Scholar Rock Holding (FRA:2QK) EBIT: €-345.10 Mil (TTM As of Mar. 2026)


FRA:2QK Scholar Rock Holding Corp FRA:2QK
28 GF Score
Price €45.71
! 5 Warning Signs
View Full Analysis

What is Scholar Rock Holding EBIT?

Scholar Rock Holding FRA:2QK +2.17% 28 EBIT is €-345.10 Mil as of Mar. 2026. GuruFocus rates FRA:2QK with a GF Score™ of 28/100. The stock has 5 warning signs investors should review.

Scholar Rock Holding's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was €-89.28 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was €-345.10 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Scholar Rock Holding's annualized ROC % for the quarter that ended in Mar. 2026 was -1,619.08%. Scholar Rock Holding's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -3,512.34%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Scholar Rock Holding's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -6.35%.


Scholar Rock Holding  (FRA:2QK) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Scholar Rock Holding's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-352.976 * ( 1 - 0% )/( (21.072 + 22.53)/ 2 )
=-352.976/21.801
=-1,619.08 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=345.248 - 42.588 - ( 313.899 - max(0, 47.328 - 328.916+313.899))
=21.072

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Scholar Rock Holding's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-357.1/( ( (10.322 + max(-29.961, 0)) + (10.012 + max(-34.346, 0)) )/ 2 )
=-357.1/( ( 10.322 + 10.012 )/ 2 )
=-357.1/10.167
=-3,512.34 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 12.627) - (42.588 + 0 + 0)
=-29.961

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 11.989) - (46.335 + 0 + 0)
=-34.346

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Scholar Rock Holding's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-345.101/5435.542
=-6.35 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Scholar Rock Holding EBIT Related Terms


Scholar Rock Holding EBIT Historical Data

* Premium members only.

The historical data trend for Scholar Rock Holding's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scholar Rock Holding EBIT Chart

Scholar Rock Holding Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -114.98 -126.85 -157.08 -228.68 -316.87

Scholar Rock Holding Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -67.44 -94.35 -85.96 -75.52 -89.28

FRA:2QK vs COGT, TGTX, RYTM: EBIT Comparison

For the Biotechnology subindustry, Scholar Rock Holding's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scholar Rock Holding EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scholar Rock Holding's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Scholar Rock Holding's EV-to-EBIT falls into.


FRA:2QK
28GF Score
Scholar Rock Holding Corp FRA:2QK
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scholar Rock Holding EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-345.10 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €-345.10 Mil mean?
Scholar Rock Holding (FRA:2QK) has a EBIT of €-345.10 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Scholar Rock Holding.
Is Scholar Rock Holding's EBIT too high?
Scholar Rock Holding's current EBIT is €-345.10 Mil. Overall, Scholar Rock Holding has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Scholar Rock Holding's EBIT compare to COGT and TGTX?
Scholar Rock Holding's EBIT of €-345.10 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Scholar Rock Holding. Scholar Rock Holding's current EBIT is €-345.10 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scholar Rock Holding stock overvalued right now?
Scholar Rock Holding (FRA:2QK) has a current EBIT of €-345.10 Mil. The current EBIT is €-345.10 Mil. Scholar Rock Holding's overall GF Score™ is 28/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Scholar Rock Holding (FRA:2QK), the current EBIT is €-345.10 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Scholar Rock Holding Business Description

Other Exchanges SRRK:USA2QK:Germany
Address 301 Binney Street, 3rd Floor, Cambridge, MA, USA, 02142
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
28GF Score

Get the complete analysis for FRA:2QK

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€45.71
Price